Johansson, L.
Johansson, H.
Axelsson, K. F.
Litsne, H.
Harvey, N. C.
Liu, E.
Leslie, W. D.
Vandenput, L.
McCloskey, E.
Kanis, J. A.
Lorentzon, M.
Funding for this research was provided by:
Vetenskapsrådet
Sahlgrenska Universitetssjukhuset
University of Gothenburg
Article History
Received: 1 February 2022
Accepted: 22 March 2022
First Online: 22 April 2022
Declarations
:
: All subjects signed an informed consent prior to participation. The study has been approved by the regional Ethics Review Board in Gothenburg.
: M. Lorentzon has received lecture fees from Amgen, Astellas, Lilly, Meda, Renapharma, UCB Pharma, and consulting fees from Amgen, Radius Health, UCB Pharma, Renapharma, and Consilient Health. N. Harvey has received consultancy, lecture fees, and honoraria from Alliance for Better Bone Health, Amgen, MSD, Eli Lilly, Servier, Shire, UCB, Kyowa Kirin, Consilient Healthcare, Radius Health, and Internis Pharma. E. McCloskey has received research funding, consultancy, lecture fees, and/or honoraria from Amgen, AstraZeneca, Consilient Healthcare, Fresenius Kabi, GSK, Hologic, Internis, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Servier, Synexus, UCB, Unilever, and Warner Chilcott. All other authors state that they have no conflicts of interests.